pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,706 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT820Endpoints617BioPharma Dive237onclive165BioSpace85Fierce Biotech84raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Nourish raises $100M for virtual nutrition care
    Nourish, a telehealth platform that arranges virtual appointments with nutritionists, just raised a new round that bumped its valuation to $1.75 billion, according to a person familiar with the mat…
    Endpoints · 2mo ago↗ source
  • STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
    A new set of lists ranks drug company laboratories on two criteria: innovation and invention.
    STAT · 2mo ago↗ source
  • The latest on Ebola: A travel ban and an old vaccine
    Affordable Care Act changes, drinking while pregnant, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
← prev
page 47 of 69
next →
21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
    Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer. The biotech on Tu…
    Endpoints · 2mo ago↗ source
  • BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
    BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the ENPP…
    Endpoints · 2mo ago↗ source
  • STAT+: 1 in 8 women drink during pregnancy. Experts dread the consequences
    More than 1 in 8 pregnant women report drinking. Doctors warn fetal alcohol disorders may be more common than many realize, perhaps more common than autism.
    STAT · 2mo ago↗ source
  • Opinion: Britain embraces a Massachusetts experiment on tobacco regulation — just as the state might roll it back
    Britain embraces a Massachusetts experiment on tobacco regulation — just as the commonwealth might roll it back.
    STAT · 2mo ago↗ source
  • Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive
    “On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.
    STAT · 2mo ago↗ source
  • STAT+: Maryland state affordability board places a price cap on Ozempic
    Nine states have been pursuing the idea of prescription drug affordability boards. Maryland's board just set limits on the price of Ozempic.
    STAT · 2mo ago↗ source
  • STAT+: White House taps Amazon, GoodRx, and Mark Cuban to bolster TrumpRx
    Trump's drug discount platform adds 600 generic medications via major online pharmacies.
    STAT · 2mo ago↗ source
  • With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
    With no approved vaccine for the fast-growing Ebola outbreak in the DRC, experts weigh testing one with unknown protection.
    STAT · 2mo ago↗ source
  • STAT+: Trump’s CMS to allow skimpier plans on ACA exchanges
    The new plans could leave patients on the hook for more of their health care costs.
    STAT · 2mo ago↗ source
  • Amgen stands by rare disease drug Tavneos amid Japan liver toxicity report
    The FDA wants it off the market. European regulators are investigating data-integrity concerns. And now, a pharma company selling the drug in Japan is warning doctors against writing new prescripti…
    Endpoints · 2mo ago↗ source
  • FDA's unreleased Covid vaccine deaths report is published by lawmaker
    An analysis launched by former FDA leaders to look into claims of pediatric deaths related to Covid-19 vaccines was published by a Republican lawmaker, months after the agency's self-imposed deadli…
    Endpoints · 2mo ago↗ source
  • STAT+: Why the WakeMed – Atrium Health hospital merger matters
    Hospital execs worked in secret on the deal for two years.
    STAT · 2mo ago↗ source
  • STAT+: AstraZeneca picks up FDA approval for hypertension drug
    The China question, FDA leadership shakeups, and other biotech news from The Readout
    STAT · 2mo ago↗ source
  • U.S. bans entry from Ebola-affected countries as American patient is identified
    In response to an Ebola outbreak, the U.S. has banned entry for noncitizens who have been in the Democratic Republic of the Congo, Uganda, or South Sudan recently.
    STAT · 2mo ago↗ source
  • FDA approves AstraZeneca’s new kind of hypertension drug
    Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
    BioPharma Dive · 2mo ago↗ source
  • Merck ADC, licensed from China, hits mark in first big global trial
    The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
    BioPharma Dive · 2mo ago↗ source
  • Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
    As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion. Parabi…
    Endpoints · 2mo ago↗ source
  • Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China
    Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improveme…
    Endpoints · 2mo ago↗ source
  • Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
    The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
    BioPharma Dive · 2mo ago↗ source
  • Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
    An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the pat…
    Endpoints · 2mo ago↗ source
  • STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
    The rejection may make the pharma firms remaining lawsuits more difficult.
    STAT · 2mo ago↗ source
  • The Supreme Court won't take up drugmakers' IRA cases
    The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca,…
    Endpoints · 2mo ago↗ source